Bristol-Myers Squibb

Bristol-Myers Squibb Co Sees Stake Raised by NOVEM GROUP, Q3 Earnings Beat Expectations

Bristol-Myers Squibb Co. (BMY) Shares Rise 3.76% on February 6

Wells Fargo

Wells Fargo Raises Bristol-Myers Squibb Price Target to $60.00

Bristol-Myers Squibb Co Stake Increased by Stone Summit Wealth LLC, Reaching 12,100 Shares Valued at $652,670

百时美施贵宝

Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises PT to $64.

Catalyst<ul> <li>Most analysts rate BMY Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Net outflow trends across all fund size categories indicate declining investor confidence.</li> <li>Market expectations tend to be pessimistic, with analysts showing differing views on BMY's outlook.</li></ul>

Key Factors

Bristol-Myers Squibb raised its 2026 revenue guidance to $46–$47.5 billion driven by growth portfolio performance. Bristol-Myers Squibb signed a multi-year manufacturing deal with Oxford Biomedica for CAR-T therapy programs. Bristol-Myers Squibb's Q4 2025 earnings beat expectations with revenue of $12.5 billion and adjusted EPS of $1.26. Bristol-Myers Squibb partnered with Kasey Keller to raise lymphoma awareness and promote Breyanzi treatment. Bristol-Myers Squibb's growth portfolio reached $7.4 billion in revenue, accounting for nearly 60% of total sales.

Recent Updates

BMY News